EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Adverse event

Conditions

Diabetic Macular Edema
Branch Retinal Vein Occlusion
Glaucoma/Closed Angle Glaucoma

Interventions

DRUG: IRX-101
DRUG: Control

Sponsor

iRenix Medical, Inc.